Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Non-Current Debt (2016 - 2025)

STRATA Skin Sciences' Non-Current Debt history spans 12 years, with the latest figure at $13.4 million for Q3 2025.

  • On a quarterly basis, Non-Current Debt fell 11.34% to $13.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.4 million, a 11.34% decrease, with the full-year FY2024 number at $15.2 million, up 0.98% from a year prior.
  • Non-Current Debt hit $13.4 million in Q3 2025 for STRATA Skin Sciences, down from $15.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for SSKN hit a ceiling of $15.3 million in Q2 2025 and a floor of $497000.0 in Q2 2021.
  • Historically, Non-Current Debt has averaged $10.7 million across 5 years, with a median of $13.4 million in 2025.
  • Biggest five-year swings in Non-Current Debt: crashed 71.26% in 2021 and later surged 1387.93% in 2022.
  • Tracing SSKN's Non-Current Debt over 5 years: stood at $7.3 million in 2021, then increased by 2.15% to $7.5 million in 2022, then surged by 101.23% to $15.0 million in 2023, then rose by 0.98% to $15.2 million in 2024, then decreased by 11.57% to $13.4 million in 2025.
  • Business Quant data shows Non-Current Debt for SSKN at $13.4 million in Q3 2025, $15.3 million in Q2 2025, and $15.2 million in Q1 2025.